[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BPharmCatalyst BioPharmCatalyst BioPharmCatalyst posts on X about $evax, $telo, $gnpx, $valn the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::56121651/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXXXX +66% - X Year XXXXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::56121651/posts_active)  - X Week XX +14% - X Month XX -XX% - X Months XXX -XXXX% - X Year XXX +22% ### Followers: XXXXXX [#](/creator/twitter::56121651/followers)  - X Week XXXXXX +0.13% - X Month XXXXXX +0.79% - X Months XXXXXX +3.50% - X Year XXXXXX +5.30% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::56121651/influencer_rank)  ### Social Influence [#](/creator/twitter::56121651/influence) --- **Social category influence** [cryptocurrencies](/list/cryptocurrencies) XXXX% [finance](/list/finance) XXXX% [stocks](/list/stocks) XXXX% **Social topic influence** [$evax](/topic/$evax) #3, [$telo](/topic/$telo) 1.27%, [$gnpx](/topic/$gnpx) #15, [$valn](/topic/$valn) 1.27%, [$axgn](/topic/$axgn) 1.27%, [$oabi](/topic/$oabi) #1, [$coya](/topic/$coya) 1.27%, [$bmea](/topic/$bmea) 1.27%, [$lptx](/topic/$lptx) 1.27%, [$sprb](/topic/$sprb) XXXX% **Top accounts mentioned or mentioned by** [@yusufhameed](/creator/undefined) [@beallucanbe3](/creator/undefined) [@artsstocks](/creator/undefined) [@ti60123bg](/creator/undefined) [@marketwirenews](/creator/undefined) [@hivolbreakouts](/creator/undefined) [@thenorthstar5](/creator/undefined) [@streetcred2017](/creator/undefined) [@meyer_adri74674](/creator/undefined) [@varro_analytics](/creator/undefined) [@brantandre88074](/creator/undefined) [@henrywalke70493](/creator/undefined) [@aponiaanalytics](/creator/undefined) [@ripster47](/creator/undefined) [@augustine_astr](/creator/undefined) [@asset_smind](/creator/undefined) [@ceciliacas81917](/creator/undefined) [@seanluomdphd](/creator/undefined) [@clairefarrngoat](/creator/undefined) [@earthling_777](/creator/undefined) **Top assets mentioned** [One Cash (ONC)](/topic/$onc) [BOLT Token (BOLT)](/topic/$bolt) [CheckDot (CDT)](/topic/$cdt) [Boston Scientific Corporation (BSX)](/topic/boston-scientific) [Tourmaline Bio, Inc. Common Stock (TRML)](/topic/$trml) [Byepix (EPIX)](/topic/$epix) [Huma Finance (HUMA)](/topic/$huma) [Immunovant, Inc. Common Stock (IMVT)](/topic/$imvt) [Vaxcyte, Inc. Common Stock (PCVX)](/topic/$pcvx) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Akropolis (AKRO)](/topic/$akro) [Apogee Therapeutics, Inc. Common Stock (APGE)](/topic/$apge) ### Top Social Posts [#](/creator/twitter::56121651/posts) --- Top posts by engagements in the last XX hours "$ELUT agreed to sell its cardiac device business to Boston Scientific for $88M enabling debt elimination and a strategic shift toward its breast reconstruction-focused SimpliDerm franchise and drug-eluting pipeline aiming to improve financial stability and preserve shareholder value without dilution. $TRML $ELUT $CELU $RENB $REVB $TELO $XLO See More Biotech Updates👇 link" [X Link](https://x.com/BPharmCatalyst/status/1965513150960119968) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-09-09T20:30Z 30.4K followers, 1885 engagements "$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. $GNPX $ATXS $NDRA $RCKT $GDTC $SBFM $EVAX $SNTI $CERO $IVVD See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1978197105635143722) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-14T20:31Z 30.4K followers, 3441 engagements "$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1978440788246724827) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-15T12:40Z 30.4K followers, 12.5K engagements "$VALN announced that the FDA has suspended the license for IXCHIQ citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires $AXGN $MNKD $SCHP $OABI $ONC $COYA $ARTL $EQ See More Pre-market Movers👇" [X Link](https://x.com/BPharmCatalyst/status/1959957544194940942) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-08-25T12:34Z 30.4K followers, 2533 engagements "$VALN announced that the FDA has suspended the license for IXCHIQ citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires $AXGN $MNKD $SCHP $OABI $ONC $COYA $ARTL $EQ See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1959959005838622759) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-08-25T12:40Z 30.4K followers, 2492 engagements "$SER announced FDA feedback supporting advancement of SER-252 (POZ-apomorphine) into a registrational program for advanced Parkinsons under the 505(b)(2) NDA pathway. $AXGN $VALN $HCWB $SCPH $OABI $ACHV $COYA $IMRX $EPIX See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1960077321802543408) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-08-25T20:30Z 30.4K followers, 3188 engagements "$BMEA reported 52-week Phase II COVALENT-111 data for icovamenib showing a durable XXX% placebo-adjusted HbA1c reduction sustained nine months post-treatment and strong responses in patients unresponsive to GLP-1 therapies with a favorable safety profile; Phase II trials in insulin-deficient and GLP-1-refractory diabetes are set to begin in Q4 2025. $STEX $BMEA $SKYE $GANX $BOLT $BFLY $LPTX $EVAX $ADAP $ACIU See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1975297740025344171) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-06T20:30Z 30.4K followers, 2683 engagements "$BMEA priced a public offering raising approximately $XXXX million through the sale of XXXX million shares and X million pre-funded warrants each paired with a warrant exercisable at $XXXX for three years. The offering priced at $XXXX per unit includes a 30-day underwriter option to purchase up to XXXX million additional shares or warrants. $SPRB $BMEA $LXEO $TELO $LPTX $JBIO $GLTO $PCSA $DRMA $FEMY See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1975543469746667993) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-07T12:47Z 30.4K followers, 2104 engagements "$SPRB shares closed up after the FDA granted Breakthrough Therapy designation to tralesinidase alfa for Sanfilippo Syndrome Type B a rare pediatric neurodegenerative disorder. The company plans to file for U.S. approval in the first quarter of 2026. $SPRB $BMEA $HUMA $TELO $LXEO $LPTX $GLTO $XBIO $EVAX $CLRB See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1975660419827028191) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-07T20:32Z 30.4K followers, 2266 engagements "$SPRB secured $50M in a private placement to fund advancement of tralesinidase alfa for Sanfilippo Syndrome Type B (MPS IIIB) through BLA submission in Q1 2026 targeting a potential U.S. commercial launch by late 2026. $ESPR $SPRB $KPTI $RNAZ $VRCA $RBOT $XBIO $ACXP $GLTO $BJDX See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1975904077629321268) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-08T12:40Z 30.4K followers, 3011 engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next X months $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM" [X Link](https://x.com/BPharmCatalyst/status/1977016053541879867) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-11T14:18Z 30.4K followers, 1934 engagements "$RAPP announced that its lead candidate RAP-219 met primary and key secondary endpoints in a Phase 2a trial for drug-resistant focal onset seizures demonstrating a XXXX% median seizure reduction and XX% seizure freedom with strong safety and tolerability. $DNTH $SMMT $IDYA $SINT $EDAP $XAIR See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1965032454596497564) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-09-08T12:40Z 30.4K followers, 3569 engagements "$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC 2025 complementing upcoming two-year efficacy results from its Phase X KEYTRUDA combination trial being presented at ESMO 2025. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1974210485022085549) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-03T20:30Z 30.4K followers, 3413 engagements "$CDT announced a 1-for-8 reverse stock split approved by its board aiming to enhance capital-raising flexibility as part of its strategic execution following prior shareholder authorization granted in May 2025. $BJDX $CDT $AKRO $APGE $ATHE $NGNE $TCRT $BDRX $PCSA $GTBP See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1976266478425915437) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-09T12:40Z 30.4K followers, 1966 engagements "$SHPH signed a letter of intent to acquire for $10M in cash and stock adding an AI-driven drug discovery platform that accelerates candidate identification and integrates autonomous workflows to enhance Shuttles therapeutic development capabilities. $SHPH $CARM $ARAY $CDT $ATYR $CDTX $ADTX $LITS $IVA $KIDS See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1976628859224154616) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-10T12:40Z 30.4K followers, 1654 engagements "$NDRA secured $XXX million in a private placement led by institutional and crypto investors selling stock and warrants at $XXXX per unit to fund a digital asset treasury strategy focused on Arcas high-conviction DeFi holdings marking a pivot toward blockchain-linked capital deployment alongside its core MASLD/MASH imaging focus. $TRVD $CGEN $RCUS $MNPR $NDRA $SRRK $NBTX $APLT $QNRX $ADTX See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1977834368639832089) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-13T20:30Z 30.4K followers, 1935 engagements "$OMER signed a definitive agreement to sell global rights of its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $340M upfront and near-term milestones with total deal value up to $2.1B plus tiered royalties giving Novo full control over development and commercialization in rare blood and kidney disorders. $GNPX $OMER $SPRC $EVAX $ENVB $SBFM $TOVX $SANA $AKTX $GANX See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1978560064437825681) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-15T20:34Z 30.4K followers, 2096 engagements "$BCRX and $ATXS announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases for a mix of cash and stock representing an implied value of $XXXXX per Astria share and approximately $XXX million in enterprise value. $ATXS $IPHA $NDRA $RCKT $SBFM $GDTC $ELAB $GNPX $NBTX $DBVT See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1978078417846149238) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-14T12:40Z 30.4K followers, 1971 engagements "$RANI signed a $1.085B potential collaboration with Chugai receiving $10M upfront and up to $175M in milestones and royalties for the lead oral biologic using its RaniPill platform; alongside a $60.3M oversubscribed private placement and $28M in expected Chugai payments Rani is now funded into 2028 to advance its oral biologics pipeline. $RANI $ARTV $XRTX $KZR $ACHV $PLX $AKAN $IRON $RCEL $NIVF See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1979165574019068232) [@BPharmCatalyst](/creator/x/BPharmCatalyst) 2025-10-17T12:40Z 30.4K followers, 1676 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BPharmCatalyst BioPharmCatalyst
BioPharmCatalyst posts on X about $evax, $telo, $gnpx, $valn the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXXXX +66%
- X Year XXXXXXXXX -XX%
Mentions: XX #
- X Week XX +14%
- X Month XX -XX%
- X Months XXX -XXXX%
- X Year XXX +22%
Followers: XXXXXX #
- X Week XXXXXX +0.13%
- X Month XXXXXX +0.79%
- X Months XXXXXX +3.50%
- X Year XXXXXX +5.30%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence cryptocurrencies XXXX% finance XXXX% stocks XXXX%
Social topic influence $evax #3, $telo 1.27%, $gnpx #15, $valn 1.27%, $axgn 1.27%, $oabi #1, $coya 1.27%, $bmea 1.27%, $lptx 1.27%, $sprb XXXX%
Top accounts mentioned or mentioned by @yusufhameed @beallucanbe3 @artsstocks @ti60123bg @marketwirenews @hivolbreakouts @thenorthstar5 @streetcred2017 @meyer_adri74674 @varro_analytics @brantandre88074 @henrywalke70493 @aponiaanalytics @ripster47 @augustine_astr @asset_smind @ceciliacas81917 @seanluomdphd @clairefarrngoat @earthling_777
Top assets mentioned One Cash (ONC) BOLT Token (BOLT) CheckDot (CDT) Boston Scientific Corporation (BSX) Tourmaline Bio, Inc. Common Stock (TRML) Byepix (EPIX) Huma Finance (HUMA) Immunovant, Inc. Common Stock (IMVT) Vaxcyte, Inc. Common Stock (PCVX) Summit Therapeutics Inc. Common Stock (SMMT) IDEAYA Biosciences, Inc. Common Stock (IDYA) Akropolis (AKRO) Apogee Therapeutics, Inc. Common Stock (APGE)
Top Social Posts #
Top posts by engagements in the last XX hours
"$ELUT agreed to sell its cardiac device business to Boston Scientific for $88M enabling debt elimination and a strategic shift toward its breast reconstruction-focused SimpliDerm franchise and drug-eluting pipeline aiming to improve financial stability and preserve shareholder value without dilution. $TRML $ELUT $CELU $RENB $REVB $TELO $XLO See More Biotech Updates👇 link"
X Link @BPharmCatalyst 2025-09-09T20:30Z 30.4K followers, 1885 engagements
"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. $GNPX $ATXS $NDRA $RCKT $GDTC $SBFM $EVAX $SNTI $CERO $IVVD See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-14T20:31Z 30.4K followers, 3441 engagements
"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-15T12:40Z 30.4K followers, 12.5K engagements
"$VALN announced that the FDA has suspended the license for IXCHIQ citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires $AXGN $MNKD $SCHP $OABI $ONC $COYA $ARTL $EQ See More Pre-market Movers👇"
X Link @BPharmCatalyst 2025-08-25T12:34Z 30.4K followers, 2533 engagements
"$VALN announced that the FDA has suspended the license for IXCHIQ citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires $AXGN $MNKD $SCHP $OABI $ONC $COYA $ARTL $EQ See More Pre-market Movers"
X Link @BPharmCatalyst 2025-08-25T12:40Z 30.4K followers, 2492 engagements
"$SER announced FDA feedback supporting advancement of SER-252 (POZ-apomorphine) into a registrational program for advanced Parkinsons under the 505(b)(2) NDA pathway. $AXGN $VALN $HCWB $SCPH $OABI $ACHV $COYA $IMRX $EPIX See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-08-25T20:30Z 30.4K followers, 3188 engagements
"$BMEA reported 52-week Phase II COVALENT-111 data for icovamenib showing a durable XXX% placebo-adjusted HbA1c reduction sustained nine months post-treatment and strong responses in patients unresponsive to GLP-1 therapies with a favorable safety profile; Phase II trials in insulin-deficient and GLP-1-refractory diabetes are set to begin in Q4 2025. $STEX $BMEA $SKYE $GANX $BOLT $BFLY $LPTX $EVAX $ADAP $ACIU See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-06T20:30Z 30.4K followers, 2683 engagements
"$BMEA priced a public offering raising approximately $XXXX million through the sale of XXXX million shares and X million pre-funded warrants each paired with a warrant exercisable at $XXXX for three years. The offering priced at $XXXX per unit includes a 30-day underwriter option to purchase up to XXXX million additional shares or warrants. $SPRB $BMEA $LXEO $TELO $LPTX $JBIO $GLTO $PCSA $DRMA $FEMY See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-07T12:47Z 30.4K followers, 2104 engagements
"$SPRB shares closed up after the FDA granted Breakthrough Therapy designation to tralesinidase alfa for Sanfilippo Syndrome Type B a rare pediatric neurodegenerative disorder. The company plans to file for U.S. approval in the first quarter of 2026. $SPRB $BMEA $HUMA $TELO $LXEO $LPTX $GLTO $XBIO $EVAX $CLRB See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-07T20:32Z 30.4K followers, 2266 engagements
"$SPRB secured $50M in a private placement to fund advancement of tralesinidase alfa for Sanfilippo Syndrome Type B (MPS IIIB) through BLA submission in Q1 2026 targeting a potential U.S. commercial launch by late 2026. $ESPR $SPRB $KPTI $RNAZ $VRCA $RBOT $XBIO $ACXP $GLTO $BJDX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-08T12:40Z 30.4K followers, 3011 engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next X months $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM"
X Link @BPharmCatalyst 2025-10-11T14:18Z 30.4K followers, 1934 engagements
"$RAPP announced that its lead candidate RAP-219 met primary and key secondary endpoints in a Phase 2a trial for drug-resistant focal onset seizures demonstrating a XXXX% median seizure reduction and XX% seizure freedom with strong safety and tolerability. $DNTH $SMMT $IDYA $SINT $EDAP $XAIR See More Pre-market Movers"
X Link @BPharmCatalyst 2025-09-08T12:40Z 30.4K followers, 3569 engagements
"$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC 2025 complementing upcoming two-year efficacy results from its Phase X KEYTRUDA combination trial being presented at ESMO 2025. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-03T20:30Z 30.4K followers, 3413 engagements
"$CDT announced a 1-for-8 reverse stock split approved by its board aiming to enhance capital-raising flexibility as part of its strategic execution following prior shareholder authorization granted in May 2025. $BJDX $CDT $AKRO $APGE $ATHE $NGNE $TCRT $BDRX $PCSA $GTBP See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-09T12:40Z 30.4K followers, 1966 engagements
"$SHPH signed a letter of intent to acquire for $10M in cash and stock adding an AI-driven drug discovery platform that accelerates candidate identification and integrates autonomous workflows to enhance Shuttles therapeutic development capabilities. $SHPH $CARM $ARAY $CDT $ATYR $CDTX $ADTX $LITS $IVA $KIDS See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-10T12:40Z 30.4K followers, 1654 engagements
"$NDRA secured $XXX million in a private placement led by institutional and crypto investors selling stock and warrants at $XXXX per unit to fund a digital asset treasury strategy focused on Arcas high-conviction DeFi holdings marking a pivot toward blockchain-linked capital deployment alongside its core MASLD/MASH imaging focus. $TRVD $CGEN $RCUS $MNPR $NDRA $SRRK $NBTX $APLT $QNRX $ADTX See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-13T20:30Z 30.4K followers, 1935 engagements
"$OMER signed a definitive agreement to sell global rights of its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $340M upfront and near-term milestones with total deal value up to $2.1B plus tiered royalties giving Novo full control over development and commercialization in rare blood and kidney disorders. $GNPX $OMER $SPRC $EVAX $ENVB $SBFM $TOVX $SANA $AKTX $GANX See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-15T20:34Z 30.4K followers, 2096 engagements
"$BCRX and $ATXS announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases for a mix of cash and stock representing an implied value of $XXXXX per Astria share and approximately $XXX million in enterprise value. $ATXS $IPHA $NDRA $RCKT $SBFM $GDTC $ELAB $GNPX $NBTX $DBVT See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-14T12:40Z 30.4K followers, 1971 engagements
"$RANI signed a $1.085B potential collaboration with Chugai receiving $10M upfront and up to $175M in milestones and royalties for the lead oral biologic using its RaniPill platform; alongside a $60.3M oversubscribed private placement and $28M in expected Chugai payments Rani is now funded into 2028 to advance its oral biologics pipeline. $RANI $ARTV $XRTX $KZR $ACHV $PLX $AKAN $IRON $RCEL $NIVF See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-17T12:40Z 30.4K followers, 1676 engagements